# US 2006/0040850 A1 · Use of enzyme inhibitors with aminopeptidase n and/or dipeptidylpeptidase IV activities and pharmaceutical preparations produced therefrom for the therapy and prevention of dermatological diseases with seborrhoeic hyperproliferation and altered differentiation states

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2006/0040850 A1
- Document ID: US20060040850A1
- Status: Published application
- Kind: A1
- Application number: 10/507,548
- Filed: 2003-03-07
- Published: 2006-02-23
- Earliest claimed: 2002-03-15
- Assignees: IMTM GmbH
- Inventors: Siegfried Ansorge; Harald Gollnick; Klaus Neubert; Christos Zouboulis; Jurgen Faust; Uwe Lendeckel; Dirk Reinhold; Robert Vetter
- Web page: https://patentgrep.com/patent/US20060040850A1

## CPC

- A61K 31/195: having an amino group
- A61K 38/05: Dipeptides
- A61K 38/55: Protease inhibitors
- A61P 17/00: Drugs for dermatological disorders
- A61P 17/08: Antiseborrheics
- A61P 17/10: Anti-acne agents
- A61P 17/14: for baldness or alopecia
- A61P 35/00: Antineoplastic agents
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The invention relates to a process for the-inhibition of the DNA synthesis necessary for the proliferation of human sebaceous cells (sebocytes) by the isolated or joint effect of inhibitors of alanyl aminopeptidase (APN) and dipetidyl peptidase IV (DP IV) expressed by these cells. The DNA synthesis (proliferation) of human sebaceous cells is inhibited by the administration of the inhibitors of APN and/or of DP IV depending on the dose. Our invention shows that, for a therapy and for a prevention of dermatological diseases with sebaceous hyperproliferation and modified conditions of differentiation, the application of inhibitors of the above-mentioned enzymes and of corresponding pharmaceutical preparations and dosage forms thereof is suitable.

## Claims

### Claim 1

A method for the preparation of pharmaceutical preparations for the inhibition of the proliferation (DNA synthesis) of human sebaceous cells comprising utilization of inhibitors of dipeptidylpeptidase IV (DP IV) as well as of inhibitors of enzymes having a similar substrate specificity (DP IV-analogous enzyme activity) and/or of inhibitors of alanyl aminopeptidase (aminopeptidase N, APN) as well as of inhibitors of enzymes having a similar substrate specificity (APN-analogous enzyme activity) for the preparation of the pharmaceutical preparations for the inhibition of the proliferation (DNA synthesis) of human sebaceous cells.

### Claim 2 (depends on 1)

The method according to claim 1, wherein the inhibitors of DP IV are selected from Xaa-Pro-dipeptides (Xaa=α-amino acid or side-chain protected derivative), corresponding derivatives, preferably dipeptide phosphonic acid diaryl esters and their salts, dipeptide boronic acids (e.g. Pro-boro-Pro) and their salts, Xaa-Xaa-(Trp)-Pro-(Xaa)n peptides (Xaa=α-amino acid, n-0 to 10), corresponding derivatives and their salts, amino acid (Xaa) amides, corresponding derivatives and their salts, wherein Xaa is an α-amino acid or a side chain-protected derivative, preferably Nε-4-nitrobenzyl oxycarbonyl-L-lysine, L-isoleucine, L-valine, L-tryptophane, L-proline, and cyclic amines as, for example, pyrrolidine, piperidine, thiazolidine and their derivatives act as the amide structure, tryptophane-1,2,3,4-tetrahydroisochinoline-3-carboxylic acid derivatives (TSL) and/or (2S,2S′,2S″)-2-[2′-[2″-amino-3″-(indol-3′″-yl)-1″-oxoprolyl-1′,2′,3′,4′-tetrahydro-6′8′-dihydroxy-7-methoxyisochinol-3-yl-carbonyl-amino]-4-hydromethyl-5-hydropentanoic acid (TMC-2A).

### Claim 3 (depends on 1)

The method according to claim 1, wherein amino acid amides are used as DP IV inhibitors, preferably Nε-4-nitrobenzyl-oxycarbonyl-L-lysine thiazolidide, pyrrolidide and piperidide as well as the corresponding 2-cyano thiazolidide, 2-cyano pyrrolidide and 2-cyano piperidide derivative.

### Claim 4 (depends on 1)

The method according to claim 1, wherein actinonin, leuhistin, phebestin, amastatin, bestatin, probestin, β-aminothiols, α-aminophosphinic acids, α-amino phospinic acid derivatives, preferably D-Phe-ψ-[PO(OH)—CH2]-Phe-Phe, and their salts act as inhibitors of APN.

### Claim 5 (depends on 1)

The method of utilizing inhibitor combinations according to claims 1 for manufacturing pharmaceutical preparations for a prevention and therapy of both benign follicular hyperproliferation conditions (acne, acneiform follicular reactions, steatocystoma multiplex, naevi of sebaceous glands, senile sebaceous gland hypertrophy, seborrhea of the skin and of the hair), SAHA syndrome [seborrhea, acne, hirsutism, alopecia] and malign folliculal hyperproliferation conditions (mixed tumors, sebaceomes, naevus sebaceous with malign development, sebaceous gland tumors, sebaceous gland CA).

### Claim 6

A method for inhibition of the proliferation (DNA systems) of human sebaceous cells comprising utilizing inhibitors of dipeptidylpeptidase IV (DP IV) as well as of inhibitors of enzymes having a similar substrate specificity (DP IV-analogous enzyme activity) and/or of inhibitors of alanyl aminopeptidase (aminopeptidase N, APN) as well as of inhibitors of enzymes having a similar substrate specificity (APN-analogous enzyme activity) for the inhabitation of the proliferation (DNA synthesis) of human sebaceous cells.

### Claim 7 (depends on 6)

The method according to claim 6, wherein the inhibitors of the DP IV are selected from Xaa-Pro-dipeptides (Xaa-α-amino acid or side-chain protected derivative), corresponding derivatives, preferably dipeptide phosphonic acid diaryl esters and their salts, dipeptide boronic acids (e.g. Pro-boro-Pro) and their salts, Xaa-Xaa-(Trp)-Pro-(Xaa)n peptides (Xaa=α-amino acid, n=0 to 10), corresponding derivatives and their salts, amino acid (Xaa) amides, corresponding derivatives and their salts, wherein Xaa is an α-amino acid or a side chain-protected derivative, preferably Nε-4-nitrobenzyloxy carbonyl-L-lysine, L-isoleucine, L-valine, L-tryptophane, L-proline, and cyclic amines, for example pyrrolidine, piperidine, thiazolidine and their derivatives act as the amide structure, tryptophane-1,2,3,4-tetrahydroisochinoline-3-carboxylic acid derivatives (TSL) and/or (2S,2S′,2S″)-2-[2′-[2″-amino-3″-(indol-3′″-yl)-1″-oxoprolyl]-1′, 2′3′,4′-tetrahydro-6′8′-dihydroxy-7-methoxyisochinol-3-yl-carbonyl-amino]-4-hydromethyl-5-hydropentanoic acid (TMC-2A).

### Claim 8 (depends on 6)

The method according to claim 6, wherein amino acid amides are used as DP IV inhibitors, preferably Nε-4-nitrobenzyl-oxycarbonyl-L-lysine thiazolidide, pyrrolidide and piperidide as well as the corresponding 2-cyano thiazolidide, 2-cyano pyrrolidide and 2-cyano piperidide derivative.

### Claim 9 (depends on 6)

The method according to claim 6, wherein actinonin, leuhistin, phebestin, amastatin, bestatin, probestin, β-aminothiols, α-aminophosphinic acids, α-amino phosphinic acid derivatives, preferably D-Phe-ψ [PO(OH)—CH2]-Phe-Phe, and their salts act as inhibitors of APN.

### Claim 10 (depends on 6)

The method of utilizing inhibitor combinations according to claims 6 for a prevention and therapy of both benign follicular hyperproliferation conditions (acne, acneiform follicular reactions, steatocystoma multiplex, naevi of sebaceous glands, senile sebaceous gland hypertrophy, seborrhea of the skin and of the hair), SAHA syndrome [seborrhea, acne, hirsutism, alopecia] and malign follicular hyperproliferation conditions (mixed tumors, sebaceomes, naevus sebaceous with malign development, sebaceous gland tumors, sebaceous gland CA).

### Claim 11

A process for the inhibition of the proliferation (DNS synthesis) of human sebaceous cells (sebocytes) including the singular or the repeated administration of a pharmaceutical preparation to a patient with the corresponding disease pattern, comprising the administration of inhibitors of dipeptidylpeptidase IV (DP IV) as well as of inhibitors of enzymes having a similar substrate specificity (DP IV-analogous enzyme activity) and/or of inhibitors of alanyl aminopeptidase (aminopeptidase N, APN) as well as of inhibitors of enzymes having a similar substrate specificity (APN-analogous enzyme activity).

### Claim 12 (depends on 11)

Process according to claim 11, wherein the inhibitors of the DP IV are selected from Xaa-Pro-dipeptides (Xaa=α-amino acid or side-chain protected derivative), corresponding derivatives, preferably dipeptide phosphonic acid diaryl esters and their salts, dipeptide boronic acids (e.g. Pro-boro-Pro) and their salts, Xaa-Xaa-(Trp)-Pro-(Xaa)n peptides (Xaa=α-amino acid, n=0 to 10), corresponding derivatives and their salts, amino acid (Xaa) amides, corresponding derivatives and their salts, wherein Xaa is an α-amino acid or a side chain-protected derivative, preferably Nε-4-nitrobenzyloxy carbonyl-L-lysine, L-isoleucine, L-valine, L-tryptophane, L-pro-line, and cyclic amines, for example pyrrolidine, piperidine, thiazolidine and their derivatives act as the amide structure, tryptophane-1,2,3,4-tetrahydroisochinoline-3-carboxylic acid derivatives (TSL) and/or (2S,2S′,2S″)-2-[2′-[2″-amino-3″-(indol-3′″-yl)-1″-oxoprolyl]-1′,2′,3′,4′-tetrahydro-6′8′-dihydroxy-7-methoxyisochinol-3-yl-carbonyl-amino]-4-hydromethyl-5-hydropentanoic acid (TMC-2A).

### Claim 13 (depends on 11)

Process according to claim 11, wherein amino acid amides are used as DP IV inhibitors, preferably Nε-4-nitrobenzyl-oxycarbonyl-L-lysine thiazolidide, pyrrolidide and piperidide as well as the corresponding 2-cyano thiazolidide, 2-cyano pyrrolidide and 2-cyano piperidide derivative.

### Claim 14 (depends on 11)

Process according to claim 11, wherein actinonin, leuhistin, phebestin, amastatin, bestatin, probestin, β-aminothiols, α-aminophosphinic acids, α-amino phosphinic acid derivatives, preferably D-Phe-ψ [PO(OH)—CH2]-Phe-Phe, and their salts act as inhibitors of APN.

### Claim 15 (depends on 11)

Process according to claims 11, for the prevention and therapy of both benign follicular hyperproliferation conditions (acne, acneiform follicular reactions, steatocystoma multiplex, naevi of sebaceous glands, senile sebaceous gland hypertrophy, seborrhea of the skin and of the hair, SAHA-syndrom [seborrhoe, acne, hirsutism, alopecia]) and malign hyperproliferation conditions (mixed tumors, sebaceomes, naevus sebaceous with malign development, sebaceous gland tumors, sebaceous gland CA) on patients including the singular or the repeated administration of a pharmaceutical preparation with one or more inhibitor(s) of DP IV and/or APN.

### Claim 16

Pharmaceutical preparations, comprising inhibitors of dipeptidylpeptidase IV (DP IV) as well as of inhibitors of enzymes having a similar substrate specificity (DP IV-analogous enzyme activity) and/or of inhibitors of alanyl aminopeptidase (aminopeptidase N, APN) as well as of inhibitors of enzymes having a similar substrate specificity (APN-analogous enzyme activity) in combination with per se known carrier substances, additives and/or auxiliary substances.

### Claim 17 (depends on 16)

Pharmaceutical preparation according to claim 16, comprising Xaa-Pro-dipeptides (Xaa=α-amino acid or side-chain protected derivatives), corresponding derivatives, preferably dipeptide phosphonic acid diaryl esters and their salts, dipeptide boronic acids (e.g. Pro-boro-Pro) and their salts, Xaa-Xaa-(Trp)-Pro-(Xaa)n peptides (Xaa=α-amino acid, n=0 to 10), corresponding derivatives and their salts, amino acid (Xaa) amides, corresponding derivatives and their salts, wherein Xaa is an α-amino acid or a side chain-protected derivative, preferably Nε-4-nitrobenzyloxycarbonyl-L-lysine, L-isoleucine, L-valine, L-tryptophane, L-proline, and cyclic amines, for example pyrrolidine, piperidine, thiazolidine and their derivatives act as the amide structure, tryptophane-1,2,3,4-tetrahydroisochinoline-3-carboxylic acid derivatives (TSL) and/or (2S,2S′,2S″)-2-[2′-[2″-amino-3″-(indol-3′″-yl)-1″-oxoprolyl]-1′,2′,3′,4′-tetrahydro-6′8′-dihydroxy-7-methoxyisochinol-3-yl-carbonyl-amino]-4-hydromethyl-5-hydropentanoic acid (TMC-2A) as the inhibitors of the DP IV.

### Claim 18 (depends on 16)

Pharmaceutical preparation according to claim 16, comprising amino acid amides, e.g. Nε-4-nitrobenzyl-oxycarbonyl-L-lysine thiazolidide, pyrrolidide and piperidide as well as the corresponding 2-cyano thiazolidide, 2-cyano pyrrolidide and 2-cyano piperidide derivative as the inhibitors of the DP IV.

### Claim 19 (depends on 16)

Pharmaceutical preparation according to claim 16, comprising actinonin, leuhistin, phebestin, amastatin, bestatin, probestin, β-aminothiols, α-aminophosphinic acids, α-amino phosphinic acid derivatives, preferably D-Phe-ψ [PO(OH)—CH2]-Phe-Phe, and their salts as inhibitors of the APN.

### Claim 20 (depends on 16)

Pharmaceutical preparation according to claim 16, comprising two or more of the inhibitors of DP IV or inhibitors of enzymes having a DP IV-analogous enzyme activity and/or inhibitors of APN or inhibitors of enzymes having an APN-analogous enzyme activity, in a spaced-apart formulation in combination with per se known carrier substances, additives and/or auxiliary substances for a simultaneous or, with respect to time, immediately successive administration with the aim of a joint effect.

### Claim 21 (depends on 16)

Pharmaceutical preparation according to claim 16 for a systemic administration for an oral, transdermal, intravenous, subcutaneous, intracutaneous, intramuscular, rectal, vaginal, sublingual application together with per se known carrier substances, additives and/or auxiliary substances.

### Claim 22 (depends on 16)

Pharmaceutical preparation according to claim 16 for a topical administration in the form of cremes, ointments, pastes, gels, solutions, sprays, liposomes or nansomes, agitated mixtures, hydrocolloid dressings, and other dermatological bases/vehicles including instillative application.

### Claim 23 (depends on 2)

The method of utilizing inhibitor combinations according to claim 2 for manufacturing pharmaceutical preparations for a prevention and therapy of both benign follicular hyperproliferation conditions (acne, acneiform follicular reactions, steatocystoma multiplex, naevi of sebaceous glands, senile sebaceous gland hypertrophy, seborrhea of the skin and of the hair), SAHA syndrome [seborrhea, acne, hirsutism, alopecia] and malign folliculal hyperproliferation conditions (mixed tumors, sebaceomes, naevus sebaceous with malign development, sebaceous gland tumors, sebaceous gland CA).

### Claim 24 (depends on 3)

The method of utilizing inhibitor combinations according to claim 3 for manufacturing pharmaceutical preparations for a prevention and therapy of both benign follicular hyperproliferation conditions (acne, acneiform follicular reactions, steatocystoma multiplex, naevi of sebaceous glands, senile sebaceous gland hypertrophy, seborrhea of the skin and of the hair), SAHA syndrome [seborrhea, acne, hirsutism, alopecia] and malign folliculal hyperproliferation conditions (mixed tumors, sebaceomes, naevus sebaceous with malign development, sebaceous gland tumors, sebaceous gland CA).

### Claim 25 (depends on 4)

The method of utilizing inhibitor combinations according to claim 4 for manufacturing pharmaceutical preparations for a prevention and therapy of both benign follicular hyperproliferation conditions (acne, acneiform follicular reactions, steatocystoma multiplex, naevi of sebaceous glands, senile sebaceous gland hypertrophy, seborrhea of the skin and of the hair), SAHA syndrome [seborrhea, acne, hirsutism, alopecia] and malign folliculal hyperproliferation conditions (mixed tumors, sebaceomes, naevus sebaceous with malign development, sebaceous gland tumors, sebaceous gland CA).

### Claim 26 (depends on 7)

The method of utilizing inhibitor combinations according to claim 7 for a prevention and therapy of both benign follicular hyperproliferation conditions (acne, acneiform follicular reactions, steatocystoma multiplex, naevi of sebaceous glands, senile sebaceous gland hypertrophy, seborrhea of the skin and of the hair), SAHA syndrome [seborrhea, acne, hirsutism, alopecia] and malign follicular hyperproliferation conditions (mixed tumors, sebaceomes, naevus sebaceous with malign development, sebaceous gland tumors, sebaceous gland CA).

### Claim 27 (depends on 8)

The method of utilizing inhibitor combinations according to claim 8 for a prevention and therapy of both benign follicular hyperproliferation conditions (acne, acneiform follicular reactions, steatocystoma multiplex, naevi of sebaceous glands, senile sebaceous gland hypertrophy, seborrhea of the skin and of the hair), SAHA syndrome [seborrhea, acne, hirsutism, alopecia] and malign follicular hyperproliferation conditions (mixed tumors, sebaceomes, naevus sebaceous with malign development, sebaceous gland tumors, sebaceous gland CA).

### Claim 28 (depends on 9)

The method of utilizing inhibitor combinations according to claim 9 for a prevention and therapy of both benign follicular hyperproliferation conditions (acne, acneiform follicular reactions, steatocystoma multiplex, naevi of sebaceous glands, senile sebaceous gland hypertrophy, seborrhea of the skin and of the hair), SAHA syndrome [seborrhea, acne, hirsutism, alopecia] and malign follicular hyperproliferation conditions (mixed tumors, sebaceomes, naevus sebaceous with malign development, sebaceous gland tumors, sebaceous gland CA).

### Claim 29 (depends on 12)

Process according to claim 12, for the prevention and therapy of both benign follicular hyperproliferation conditions (acne, acneiform follicular reactions, steatocystoma multiplex, naevi of sebaceous glands, senile sebaceous gland hypertrophy, seborrhea of the skin and of the hair, SAHA-syndrom [seborrhoe, acne, hirsutism, alopecia]) and malign hyperproliferation conditions (mixed tumors, sebaceomes, naevus sebaceous with malign development, sebaceous gland tumors, sebaceous gland CA) on patients including the singular or the repeated administration of a pharmaceutical preparation with one or more inhibitor(s) of DP IV and/or APN.

### Claim 30 (depends on 13)

Process according to claim 13, for the prevention and therapy of both benign follicular hyperproliferation conditions (acne, acneiform follicular reactions, steatocystoma multiplex, naevi of sebaceous glands, senile sebaceous gland hypertrophy, seborrhea of the skin and of the hair, SAHA-syndrom [seborrhoe, acne, hirsutism, alopecia]) and malign hyperproliferation conditions (mixed tumors, sebaceomes, naevus sebaceous with malign development, sebaceous gland tumors, sebaceous gland CA) on patients including the singular or the repeated administration of a pharmaceutical preparation with one or more inhibitor(s) of DP IV and/or APN.

### Claim 31 (depends on 14)

Process according to claim 14, for the prevention and therapy of both benign follicular hyperproliferation conditions (acne, acneiform follicular reactions, steatocystoma multiplex, naevi of sebaceous glands, senile sebaceous gland hypertrophy, seborrhea of the skin and of the hair, SAHA-syndrom [seborrhoe, acne, hirsutism, alopecia]) and malign hyperproliferation conditions (mixed tumors, sebaceomes, naevus sebaceous with malign development, sebaceous gland tumors, sebaceous gland CA) on patients including the singular or the repeated administration of a pharmaceutical preparation with one or more inhibitor(s) of DP IV and/or APN.

### Claim 32 (depends on 17)

Pharmaceutical preparation according to claim 17, comprising two or more of the inhibitors of DP IV or inhibitors of enzymes having a DP IV-analogous enzyme activity and/or inhibitors of APN or inhibitors of enzymes having an APN-analogous enzyme activity, in a spaced-apart formulation in combination with per se known carrier substances, additives and/or auxiliary substances for a simultaneous or, with respect to time, immediately successive administration with the aim of a joint effect.

### Claim 33 (depends on 18)

Pharmaceutical preparation according to claim 18, comprising two or more of the inhibitors of DP IV or inhibitors of enzymes having a DP IV-analogous enzyme activity and/or inhibitors of APN or inhibitors of enzymes having an APN-analogous enzyme activity, in a spaced-apart formulation in combination with per se known carrier substances, additives and/or auxiliary substances for a simultaneous or, with respect to time, immediately successive administration with the aim of a joint effect.

### Claim 34 (depends on 19)

Pharmaceutical preparation according to claim 19, comprising two or more of the inhibitors of DP IV or inhibitors of enzymes having a DP IV-analogous enzyme activity and/or inhibitors of APN or inhibitors of enzymes having an APN-analogous enzyme activity, in a spaced-apart formulation in combination with per se known carrier substances, additives and/or auxiliary substances for a simultaneous or, with respect to time, immediately successive administration with the aim of a joint effect.

### Claim 35 (depends on 17)

Pharmaceutical preparation according to claim 17 for a systemic administration for an oral, transdermal, intravenous, subcutaneous, intracutaneous, intramuscular, rectal, vaginal, sublingual application together with per se known carrier substances, additives and/or auxiliary substances.

### Claim 36 (depends on 18)

Pharmaceutical preparation according to claim 18 for a systemic administration for an oral, transdermal, intravenous, subcutaneous, intracutaneous, intramuscular, rectal, vaginal, sublingual application together with per se known carrier substances, additives and/or auxiliary substances.

### Claim 37 (depends on 19)

Pharmaceutical preparation according to claim 19 for a systemic administration for an oral, transdermal, intravenous, subcutaneous, intracutaneous, intramuscular, rectal, vaginal, sublingual application together with per se known carrier substances, additives and/or auxiliary substances.

### Claim 38 (depends on 20)

Pharmaceutical preparation according to claim 20 for a systemic administration for an oral, transdermal, intravenous, subcutaneous, intracutaneous, intramuscular, rectal, vaginal, sublingual application together with per se known carrier substances, additives and/or auxiliary substances.

### Claim 39 (depends on 17)

Pharmaceutical preparation according to claim 17 for a topical administration in the form of cremes, ointments, pastes, gels, solutions, sprays, liposomes or nansomes, agitated mixtures, hydrocolloid dressings, and other dermatological bases/vehicles including instillative application.

### Claim 40 (depends on 18)

Pharmaceutical preparation according to claim 18 for a topical administration in the form of cremes, ointments, pastes, gels, solutions, sprays, liposomes or nansomes, agitated mixtures, hydrocolloid dressings, and other dermatological bases/vehicles including instillative application.

### Claim 41 (depends on 19)

Pharmaceutical preparation according to claim 19 for a topical administration in the form of cremes, ointments, pastes, gels, solutions, sprays, liposomes or nansomes, agitated mixtures, hydrocolloid dressings, and other dermatological bases/vehicles including instillative application.

### Claim 42 (depends on 20)

Pharmaceutical preparation according to claim 20 for a topical administration in the form of cremes, ointments, pastes, gels, solutions, sprays, liposomes or nansomes, agitated mixtures, hydrocolloid dressings, and other dermatological bases/vehicles including instillative application.
